Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES ADDITIONAL AGREEMENT WITH LEADING BIOPHARMACEUTICAL COMPANY
Cambridge, UK, 5 July 2023. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has entered into an agreement with a leading biopharmaceutical company to support the ongoing development of a biosimilar product.
This revenue-generating collaboration follows an earlier technology partnership between the two companies, utilising Arecor’s proprietary technology platform, Arestat™, and formulation expertise.
Sarah Howell, Chief Executive Officer of Arecor, said: “This collaboration demonstrates the strength of our know-how and expertise and the value that expertise can bring to our partners’ research programmes. We’re delighted to be working again with an existing partner, strengthening a key relationship and building on our track record of partnerships with leading biopharmaceutical and biotechnology companies.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Neville Tel: +44 (0) 20 3709 5700